Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions.
Aspirin in the treatment and prevention of cardiovascular disease: current perspectives and future directions.
复制标题
DOI：
10.1007/s11883-007-0053-0
复制
发表时间：
2007-11-01
影响因子：
5.8
通讯作者：
Hennekens, Charles H
中科院分区：
文献类型：
--
作者：
Hennekens, Charles H
在既往心肌梗死（MI）、闭塞性卒中、短暂性脑缺血发作和其他高危疾病的男性和女性幸存者的二级预防中，长期使用阿司匹林可使MI、卒中和心血管死亡发生非常相似的统计学显著性和临床重要性降低。在患有急性心肌梗死或急性闭塞性卒中的男性和女性中，阿司匹林具有相似的益处。在一级预防中，阿司匹林可显著降低首次心肌梗死的风险，具有统计学意义和临床意义，但关于中风和心血管疾病死亡的数据仍不确定，因此阿司匹林应由医疗保健提供者根据个人情况开具处方，并权衡这种明显的益处与长期副作用。在世界范围内，更广泛和适当地使用阿司匹林将避免许多在二级预防、急性MI和急性卒中期间的过早死亡，以及许多在一级预防中的首次MI。
In secondary prevention among male and female survivors of prior myocardial infarction (MI), occlusive stroke, transient ischemic attack, and other high-risk conditions, long-term use of aspirin confers very similar statistically significant and clinically important reductions in MI, stroke, and cardiovascular death. In men and women suffering acute MI or acute occlusive stroke, aspirin confers similar benefits. In primary prevention, aspirin confers a statistically significant and clinically important reduction in risk of a first MI, but the data on stroke and cardiovascular disease death remain inconclusive, so aspirin should be prescribed on an individual basis by the healthcare provider who weighs this clear benefit against long-term side effects. Worldwide, aspirin used more widely and appropriately would avoid many premature deaths in secondary prevention, during acute MI, and during acute stroke, as well as many first MI in primary prevention.